Norimitsu Uza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Norimitsu Uza has a total of 311 co-authors. Here are the top co-authors by number of shared publications:
Tsutomu Chiba
93 shared publicationsMasahiro Shiokawa
Kyoto University Hospital, Kyoto, Japan
69 shared publicationsTakahisa Maruno
Kyoto University Hospital, Kyoto, Japan
63 shared publicationsHiroshi Seno
Gastroenterology and Hepatology, Kyoto University Hospital, Kyoto, Japan
62 shared publications- Yoshihiro Nishikawa
Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto, Japan
62 shared publications Tomoaki Matsumori
Department of Gastroenterology and Hepatology Kyoto University Graduate School of Medicine Kyoto Japan
59 shared publications
Latest Publications
- Open Access
- 19 August 2025
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 103 (3) , 475-483.e10
Clinical utility of suprapapillary plastic stents for lifelong biliary drainage in unresectable malignant hilar biliary obstruction
- 19 August 2025
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 103 (3) , 475-483.e10
Open AccessClinical utility of suprapapillary plastic stents for lifelong biliary drainage in unresectable malignant hilar biliary obstruction
- Open Access
- 8 January 2025
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 19 (1) , 136-144
Efficacy and Safety of a Novel Tapered-Tip Sheath System for Biliary-Lesion Tissue Sampling: A Randomized Controlled Trial
Hirokazu Okada, Norimitsu Uza, Tomoaki Matsumori, Hajime Yamazaki, Muneji Yasuda, Takeshi Kuwada, Yoshihiro Nishikawa, Takahisa Maruno, Masahiro Shiokawa, Atsushi Takai, Ken Takahashi, Akihisa Fukuda, Etsuro Hatano, Sachiko Minamiguchi, Hiroshi Seno. Gut and Liver 2025;19:136-44. https://doi.org/10.5009/gnl240349
- 8 January 2025
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 19 (1) , 136-144
Open AccessEfficacy and Safety of a Novel Tapered-Tip Sheath System for Biliary-Lesion Tissue Sampling: A Randomized Controlled Trial
Hirokazu Okada, Norimitsu Uza, Tomoaki Matsumori, Hajime Yamazaki, Muneji Yasuda, Takeshi Kuwada, Yoshihiro Nishikawa, Takahisa Maruno, Masahiro Shiokawa, Atsushi Takai, Ken Takahashi, Akihisa Fukuda, Etsuro Hatano, Sachiko Minamiguchi, Hiroshi Seno. Gut and Liver 2025;19:136-44. https://doi.org/10.5009/gnl240349
- Open Access
- 7 January 2025
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 13 (CP) , a26317538
Utility of a novel tapered-tip sheath system for preoperative mapping biopsy of biliary tract cancers
Preoperative evaluation of biliary tract cancer progression plays a critical role in assessing resectability and in selecting the appropriate surgical procedure. This study aimed to evaluate the utility of a novel tapered-tip sheath system for mapping biopsy to assess the extent of biliary tract cancer.This observational, comparative study included 32 patients who were diagnosed with biliary tract cancers and underwent mapping biopsies with the novel tapered-tip sheath system and 21 patients using the conventional methods before the period. Technical success, total biopsy time, number of biopsy specimens, appropriate tissue sampling, adverse events (AEs), and negative surgical margin in case of surgical resection were evaluated.The following were the respective results for the novel system and conventional methods groups: technical success rates, 73.3% and 48.4% (P = 0.027); total biopsy times, 11.4 and 23.5 minutes (P = 0.043); median number of specimens obtained per procedure, 6 and 3 (P < 0.001); appropriate tissue sampling rates, 86.1% and 67.2% (P < 0.001); AE rates, 2.1% and 0%; and negative surgical margin rates, 90.4% and 78.6%.Preoperative mapping biopsy using the novel tapered-tip sheath system is a promising option for assessing the extent of biliary tract cancers.
- 7 January 2025
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 13 (CP) , a26317538
Open AccessUtility of a novel tapered-tip sheath system for preoperative mapping biopsy of biliary tract cancers
Preoperative evaluation of biliary tract cancer progression plays a critical role in assessing resectability and in selecting the appropriate surgical procedure. This study aimed to evaluate the utility of a novel tapered-tip sheath system for mapping biopsy to assess the extent of biliary tract cancer.This observational, comparative study included 32 patients who were diagnosed with biliary tract cancers and underwent mapping biopsies with the novel tapered-tip sheath system and 21 patients using the conventional methods before the period. Technical success, total biopsy time, number of biopsy specimens, appropriate tissue sampling, adverse events (AEs), and negative surgical margin in case of surgical resection were evaluated.The following were the respective results for the novel system and conventional methods groups: technical success rates, 73.3% and 48.4% (P = 0.027); total biopsy times, 11.4 and 23.5 minutes (P = 0.043); median number of specimens obtained per procedure, 6 and 3 (P < 0.001); appropriate tissue sampling rates, 86.1% and 67.2% (P < 0.001); AE rates, 2.1% and 0%; and negative surgical margin rates, 90.4% and 78.6%.Preoperative mapping biopsy using the novel tapered-tip sheath system is a promising option for assessing the extent of biliary tract cancers.
- Open Access
- 9 August 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 737, 150534
Near-infrared photoimmunotherapy as a complementary modality to in situ vaccine in a preclinical pancreatic cancer model
- 9 August 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 737, 150534
Open AccessNear-infrared photoimmunotherapy as a complementary modality to in situ vaccine in a preclinical pancreatic cancer model
- Open Access
- 22 June 2023
- Published by Wiley in The Journal of Pathology
- Vol. 261 (1) , 28-42
ELF3 suppresses gallbladder cancer development through downregulation of the EREG/EGFR/mTOR complex 1 signalling pathway
The prognosis of gallbladder cancer (GBC) remains poor, and a better understanding of GBC molecular mechanisms is important. Genome sequencing of human GBC has demonstrated that loss‐of‐function mutations of E74‐like ETS transcription factor 3 (ELF3) are frequently observed, with ELF3 considered to be a tumour suppressor in GBC. To clarify the underlying molecular mechanisms by which ELF3 suppresses GBC development, we performed in vivo analysis using a combination of autochthonous and allograft mouse models. We first evaluated the clinical significance of ELF3 expression in human GBC tissues and found that low ELF3 expression was associated with advanced clinical stage and deep tumour invasion. For in vivo analysis, we generated Pdx1‐Cre; KrasG12D; Trp53R172H; Elf3f/f (KPCE) mice and Pdx1‐Cre; KrasG12D; Trp53R172H; Elf3wt/wt (KPC) mice as a control and analysed their gallbladders histologically. KPCE mice developed larger papillary lesions in the gallbladder than those developed by KPC mice. Organoids established from the gallbladders of KPCE and KPC mice were analysed in vitro. RNA sequencing showed upregulated expression of epiregulin (Ereg) in KPCE organoids, and western blotting revealed that EGFR/mechanical targets of rapamycin complex 1 (mTORC1) were upregulated in KPCE organoids. In addition, ChIP assays on Elf3‐overexpressing KPCE organoids showed that ELF3 directly regulated Ereg. Ereg deletion in KPCE organoids (using CRISPR/Cas9) induced EGFR/mTORC1 downregulation, indicating that ELF3 controlled EGFR/mTORC1 activity through regulation of Ereg expression. We also generated allograft mouse models using KPCE and KPC organoids and found that KPCE organoid allograft tumours exhibited poorly differentiated structures with mTORC1 upregulation and mesenchymal phenotype, which were suppressed by Ereg deletion. Furthermore, EGFR/mTORC1 inhibition suppressed cell proliferation and epithelial–mesenchymal transition in KPCE organoids. Our results suggest that ELF3 suppresses GBC development via downregulation of EREG/EGFR/mTORC1 signalling. EGFR/mTORC1 inhibition is a potential therapeutic option for GBC with ELF3 mutation. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
- 22 June 2023
- Published by Wiley in The Journal of Pathology
- Vol. 261 (1) , 28-42
Open AccessELF3 suppresses gallbladder cancer development through downregulation of the EREG/EGFR/mTOR complex 1 signalling pathway
The prognosis of gallbladder cancer (GBC) remains poor, and a better understanding of GBC molecular mechanisms is important. Genome sequencing of human GBC has demonstrated that loss‐of‐function mutations of E74‐like ETS transcription factor 3 (ELF3) are frequently observed, with ELF3 considered to be a tumour suppressor in GBC. To clarify the underlying molecular mechanisms by which ELF3 suppresses GBC development, we performed in vivo analysis using a combination of autochthonous and allograft mouse models. We first evaluated the clinical significance of ELF3 expression in human GBC tissues and found that low ELF3 expression was associated with advanced clinical stage and deep tumour invasion. For in vivo analysis, we generated Pdx1‐Cre; KrasG12D; Trp53R172H; Elf3f/f (KPCE) mice and Pdx1‐Cre; KrasG12D; Trp53R172H; Elf3wt/wt (KPC) mice as a control and analysed their gallbladders histologically. KPCE mice developed larger papillary lesions in the gallbladder than those developed by KPC mice. Organoids established from the gallbladders of KPCE and KPC mice were analysed in vitro. RNA sequencing showed upregulated expression of epiregulin (Ereg) in KPCE organoids, and western blotting revealed that EGFR/mechanical targets of rapamycin complex 1 (mTORC1) were upregulated in KPCE organoids. In addition, ChIP assays on Elf3‐overexpressing KPCE organoids showed that ELF3 directly regulated Ereg. Ereg deletion in KPCE organoids (using CRISPR/Cas9) induced EGFR/mTORC1 downregulation, indicating that ELF3 controlled EGFR/mTORC1 activity through regulation of Ereg expression. We also generated allograft mouse models using KPCE and KPC organoids and found that KPCE organoid allograft tumours exhibited poorly differentiated structures with mTORC1 upregulation and mesenchymal phenotype, which were suppressed by Ereg deletion. Furthermore, EGFR/mTORC1 inhibition suppressed cell proliferation and epithelial–mesenchymal transition in KPCE organoids. Our results suggest that ELF3 suppresses GBC development via downregulation of EREG/EGFR/mTORC1 signalling. EGFR/mTORC1 inhibition is a potential therapeutic option for GBC with ELF3 mutation. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
- 30 May 2023
- Published by Springer Nature in Journal of Medical Ultrasonics
- Vol. 50 (3) , 451-452
Concomitant occurrence of pancreatic cancer during long-term follow-up for serous neoplasms
- 30 May 2023
- Published by Springer Nature in Journal of Medical Ultrasonics
- Vol. 50 (3) , 451-452
Concomitant occurrence of pancreatic cancer during long-term follow-up for serous neoplasms
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S6 from CXCR4 in Tumor Epithelial Cells Mediates Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma
Cxcr4 KO inhibits liver metastasis in splenic injection model.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from CXCR4 in Tumor Epithelial Cells Mediates Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma
Cxcr4 KO inhibits liver metastasis in splenic injection model.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from CXCR4 in Tumor Epithelial Cells Mediates Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma
Cxcr4 KO does not affect Cxcr4 expression in immune cells of the spleen.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from CXCR4 in Tumor Epithelial Cells Mediates Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma
Cxcr4 KO does not affect Cxcr4 expression in immune cells of the spleen.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Legends from Rb and p53 Execute Distinct Roles in the Development of Pancreatic Neuroendocrine Tumors
Supplemental Figure legends and Table Legend
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Legends from Rb and p53 Execute Distinct Roles in the Development of Pancreatic Neuroendocrine Tumors
Supplemental Figure legends and Table Legend
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Rb and p53 Execute Distinct Roles in the Development of Pancreatic Neuroendocrine Tumors
Supplemental Table 1. PanNETs incidence per genotype. Figure S1: Representative images of LacZ staining in the pancreas in Pdx1-Cre;Rosa26R mice; S2: Experimental strategy for generation of Pdx1-Cre;Trp53R172H mice. S3: H&E, immunohistochemical and immunofluorescence staining of islet cells in Pdx1-Cre and Pdx1-Cre;Trp53R172H;Rbf/f mice at 2 months of age.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Rb and p53 Execute Distinct Roles in the Development of Pancreatic Neuroendocrine Tumors
Supplemental Table 1. PanNETs incidence per genotype. Figure S1: Representative images of LacZ staining in the pancreas in Pdx1-Cre;Rosa26R mice; S2: Experimental strategy for generation of Pdx1-Cre;Trp53R172H mice. S3: H&E, immunohistochemical and immunofluorescence staining of islet cells in Pdx1-Cre and Pdx1-Cre;Trp53R172H;Rbf/f mice at 2 months of age.